Comparative Pharmacology
Head-to-head clinical analysis: MPI DTPA KIT CHELATE versus YTTERBIUM YB 169 DTPA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MPI DTPA KIT CHELATE versus YTTERBIUM YB 169 DTPA.
MPI DTPA KIT - CHELATE vs YTTERBIUM YB 169 DTPA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DTPA (diethylenetriaminepentaacetic acid) chelates paramagnetic metal ions (e.g., gadolinium) to form stable complexes that alter T1 relaxation times during MRI, enhancing contrast.
Ytterbium Yb 169 DTPA is a radiopharmaceutical that emits gamma radiation. After administration, it distributes in the extracellular fluid and is cleared by glomerular filtration. Its mechanism of action is based on physical decay emission of photons for imaging, with no pharmacological effect.
Adult: 3-4 mCi (111-148 MBq) intravenously as a single dose for renal imaging.
No standard therapeutic dosing; used as a diagnostic radiopharmaceutical. Typical adult activity: 37-111 MBq (1-3 mCi) intravenous injection for cisternography or CSF shunt evaluation.
None Documented
None Documented
The terminal elimination half-life is approximately 1.7 hours in patients with normal renal function (creatinine clearance >80 mL/min); prolonged to >20 hours in severe renal impairment.
Terminal: 25-50 days (effective half-life due to physical decay of Yb-169); clinical context: imaging agent for cisternography, half-life reflects biological clearance with physical decay (T1/2 physical: 32 days)
Renal excretion accounts for >95% of the administered dose via glomerular filtration; less than 2% is excreted in feces.
Renal: >90% unchanged; biliary/fecal: <10%
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical